Befotertinib with radiation for EGFR-mutated NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted therapy (Befotertinib) combined with radiation for people with a specific EGFR mutation whose lung cancer has spread to a few spots. It aims to see if ctDNA monitoring can guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IV non-small cell lung cancer with a common EGFR mutation (exon 19 deletion or L858R).
- Your cancer has spread to no more than 3 organs and has 5 or fewer tumors outside the chest.
- You haven't had any prior treatment for advanced lung cancer (like chemo, targeted therapy, or immunotherapy).
- You are in good general health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, befotertinib, combined with chemotherapy as a first treatment for advanced lung cancer with an EGFR mutation. It aims to see if this approach can improve outcomes and uses a special blood test to guide treatment adjustments.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
Hear when a new Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.